Carrie Miceli

Dr. M Carrie Miceli is a Professor in the Department of Molecular, Immunology, and Microbiology (MIMG) at the University of California, Los Angeles (UCLA). She holds a PhD in Immunology from Duke University Medical Center (1988), a postdoctoral fellowship in Immunology at Stanford University Medical Center (1993), and a BA in Biochemistry and Cell Biology from UCSD (1983). Her research focuses on Muscle Cell Biology, Pathophysiology, and Therapeutics, particularly in Duchenne Muscular Dystrophy (DMD). She has led multiple NIH-funded projects, including grants as Principal Investigator for studies on Galectin-1 regulation and Coreceptor Modification of TCR signals.

Her research emphasizes translational approaches to address DMD, including gene therapy strategies (e.g., CRISPR-Cas9, exon skipping), biomarker discovery through transcriptomics, and therapeutic development. Key contributions include identifying dantrolene as an enhancer of exon skipping and developing patient-specific muscle models using micromolded hydrogels.

Dr. Miceli’s work bridges immunology and muscle biology, exploring how immune modulation impacts dystrophic pathology. Notable achievements include demonstrating osteopontin’s role in fibrosis and macrophage polarization in DMD. Her lab also investigates T cell signaling mechanisms, particularly the role of scaffold proteins like DLG1 in immune cell function.

Awards and honors are not explicitly listed in the provided text, though her extensive NIH funding and publication record reflect her academic impact. She collaborates widely, including with Stanley Nelson on genomic approaches to DMD. Her work is published in high-impact journals like Cell Stem Cell, Nature Immunology, and Molecular Therapy.